Neurogene Inc.

NasdaqGM:NGNE Stock Report

Market Cap: US$451.9m

Neurogene Management

Management criteria checks 3/4

Neurogene's CEO is Rachel McMinn, appointed in Jan 2018, has a tenure of 8.42 years. total yearly compensation is $3.21M, comprised of 19.3% salary and 80.7% bonuses, including company stock and options. directly owns 8.24% of the company’s shares, worth $37.25M. The average tenure of the management team and the board of directors is 2.5 years and 2.5 years respectively.

Key information

Rachel McMinn

Chief executive officer

US$3.2m

Total compensation

CEO salary percentage19.28%
CEO tenure8.4yrs
CEO ownership8.2%
Management average tenure2.5yrs
Board average tenure2.5yrs

Recent management updates

Recent updates

Analysis Article • Apr 20

Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Feb 27

Neurogene: Stock Soars On FDA Designation For Rett Gene Therapy - I'd Remain Cautious

Summary Neurogene received FDA Breakthrough Therapy Designation for NGN-401 in Rett Syndrome, driving a >25% share price surge. NGN-401 showed clinically meaningful, durable, multidomain improvements in interim Phase 1/2 data, and the pivotal Embolden trial is underway. Despite positive regulatory momentum and a strong cash runway into 2028, I maintain a Hold rating due to sector headwinds and binary risk. Upcoming 2026 catalysts include Embolden data readout and BLA submission, but failure or safety issues could leave NGNE with no clinical assets. Read the full article on Seeking Alpha
Analysis Article • Dec 31

Here's Why We're Not Too Worried About Neurogene's (NASDAQ:NGNE) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Analysis Article • Aug 13

We Think Neurogene (NASDAQ:NGNE) Can Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Mar 07

Neurogene: Potential To Target Root Cause Of Rett Syndrome With NGN-401

Summary Additional Neurogene Inc. interim update data from the phase 1/2 study, using AAV9 capsid gene therapy NGN-401 for treatment of patients with Rett syndrome, expected 2nd half of 2025. NGNE plans to provide an update on a potential registrational phase 3 study, using NGN-401 for the treatment of patients with Rett Syndrome, in the 1st half of 2025. The global Rett Syndrome market size is estimated to reach $1.6 billion by the end of 2037. Neurogene had $139 million as of September 30th of 2024 & did an oversubscribed $200 million private placement agreement; Cash on hand enough to fund operations into the 2nd half of 2027. Read the full article on Seeking Alpha
Seeking Alpha • Nov 10

Neurogene: Interesting CNS Disease Company, Data Coming Soon

Summary Neurogene, formed from multiple mergers, has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease. NGN-401, an AAV9 gene therapy for Rett Syndrome, shows early safety and efficacy but faces competition from Acadia's FDA-approved trofinetide. Financially, Neurogene has a cash runway until 2026 but may need fundraising post-positive phase 1/2 data; current valuation seems high. The investment thesis hinges on upcoming clinical data to differentiate Neurogene from competitors; cautious optimism until more data is available. Read the full article on Seeking Alpha
Seeking Alpha • Mar 26

Neurogene Stock: Gene Therapy Specialist May Break Chain Of Failed Mergers

Summary Neurogene Inc., a clinical-stage company focused on genetic medicines for rare neurological diseases, has seen a significant increase in its share price since joining the Nasdaq in December 2023. The company is progressing two drug candidates, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease, with key milestones planned for 2024. Neurogene's success will depend on the outcome of its clinical programs and the potential of its proprietary "transgene regulation technology" platform. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Rachel McMinn's remuneration changed compared to Neurogene's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$99m

Dec 31 2025US$3mUS$619k

-US$90m

Sep 30 2025n/an/a

-US$85m

Jun 30 2025n/an/a

-US$84m

Mar 31 2025n/an/a

-US$81m

Dec 31 2024US$3mUS$595k

-US$75m

Sep 30 2024n/an/a

-US$3m

Jun 30 2024n/an/a

US$2m

Mar 31 2024n/an/a

US$9m

Dec 31 2023US$1mUS$468k

US$14m

Sep 30 2023n/an/a

-US$51m

Jun 30 2023n/an/a

-US$49m

Mar 31 2023n/an/a

-US$52m

Dec 31 2022US$657kUS$448k

-US$55m

Compensation vs Market: Rachel's total compensation ($USD3.21M) is about average for companies of similar size in the US market ($USD2.59M).

Compensation vs Earnings: Rachel's compensation has been consistent with company performance over the past year.

CEO

Rachel McMinn (53 yo)

8.4yrs
Tenure
US$3,209,553
Compensation

Dr. Rachel L. McMinn, Ph D., is Director of Alliance for Regenerative Medicine. Dr. McMinn is the Founder of Neurogene Inc. and Chief Executive Officer and Executive Chair of Board since December 2023.Dr....

Leadership Team

NamePositionTenureCompensationOwnership
Rachel McMinn
Founder8.4yrsUS$3.21m8.24%
$ 37.3m
Christine Cvijic
President2.5yrsUS$2.75m0.30%
$ 1.4m
Julie Jordan
Chief Medical Officer2.4yrsUS$1.47m0.023%
$ 103.1k
Stuart Cobb
Chief Scientific Officer2.5yrsUS$784.32k0%
$ 0
Donna Cochener-Metcalfe
Senior VP2.3yrsno data0.0013%
$ 5.7k
Andrew Mulberg
Senior VP of Regulatory Affairsno datano datano data
Ricardo Jimenez
Senior Vice President of Technical Operationsno datano datano data
Arvind Sreedharan
Senior Vice President of Business Operationsno datano datano data
Christina Shafer
Chief Commercial Officerless than a yearno datano data
2.5yrs
Average Tenure
52yo
Average Age

Experienced Management: NGNE's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Rachel McMinn
Founder2.5yrsUS$3.21m8.24%
$ 37.3m
Christine Cvijic
Presidentless than a yearUS$2.75m0.30%
$ 1.4m
Robert Baffi
Independent Director2.5yrsUS$240.48k0.17%
$ 748.9k
Rohan Palekar
Independent Director4.3yrsUS$244.48k0.12%
$ 559.0k
Sarah Noonberg
Independent Director6.8yrsUS$230.48k0.13%
$ 590.4k
Cory Freedland
Lead Independent Director2.5yrsUS$239.48k0.092%
$ 416.0k
Robert Woods
Independent Director2.5yrsUS$237.48k0.092%
$ 416.0k
2.5yrs
Average Tenure
58yo
Average Age

Experienced Board: NGNE's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/09 07:55
End of Day Share Price 2026/06/09 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Neurogene Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Whitney IjemCanaccord Genuity
Gum-Ming LoweCraig-Hallum Capital Group LLC
Debjit ChattopadhyayGuggenheim Securities, LLC